NewsBenzingaHC Wainwright & Co. Maintains Buy on Halozyme Therapeutics, Raises Price Target to $130 HC Wainwright & Co. Maintains Buy on Halozyme Therapeutics, Raises Price Target to $130 Benzinga 2026.10.08 12:24 (GMT+0) Open on Benzinga Other news Here's What to Expect From ONEOK’s Next Earnings Report BofA Just Sent a Warning Shot for Apple Investors Last call to volunteer at TechCrunch Founder Summit 2026 ICANN's new round of top-level domain applications reaches 1,615, with .agent drawing 13 contenders What You Need to Know Ahead of Waste Management’s Earnings Release Uber and China’s Pony.ai plan to launch robotaxis in London
